Literature DB >> 21331665

Effects of heating coagulation of middle meningeal artery on plasma CGRP level and c-fos expression in migraine rat triggered by nitroglycerin.

Xiaofeng Zhu1, Yuechen Han, Wenping Xiong, Wenwen Liu, Sumei Lu, Jianfeng Li, Haibo Wang, Zhaomin Fan.   

Abstract

Current theory or hypothesis relevant to migraine indicates that trigeminovascular system plays a pivotal role in the pathophysiology of migraine. Particularly, release of neuropeptide and induction of c-fos like immunoreactivity (c-fos LI) within trigeminal nucleus caudalis neurons are regarded as activation markers of trigeminovascular system. In the present study, we set up a rat model for migraine triggered by nitroglycerin (NTG) and coagulated the middle meningeal artery by heating. Using this model, we determined the plasma calcitonin gene-related peptide (CGRP) level as well as the expression of c-fos in trigeminal nucleus caudalis of rats. We found that NTG led to markedly increase in plasma CGRP level and c-fos expression in trigeminal nucleus caudalis compared with the isotonic saline-treated group (P < 0.05). More importantly, heat coagulation of middle meningeal artery could decrease plasma CGRP level and c-fos expression in trigeminal nucleus caudalis (P < 0.05). Heat coagulation of middle meningeal artery may ameliorate sufferings of rat induced by NTG and play an important role in restraining the release of CGRP as well as the activation of neurons in trigeminal nucleus caudalis in rats following NTG infusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21331665     DOI: 10.1007/s10072-011-0486-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  23 in total

1.  Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model.

Authors:  E Knyihár-Csillik; J Toldi; A Mihály; B Krisztin-Péva; Z Chadaide; H Németh; R Fenyo; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

2.  Activation of trigeminovascular neurons by glyceryl trinitrate.

Authors:  G A Lambert; C Donaldson; P M Boers; A S Zagami
Journal:  Brain Res       Date:  2000-12-22       Impact factor: 3.252

Review 3.  Animal models of migraine: looking at the component parts of a complex disorder.

Authors:  A Bergerot; P R Holland; S Akerman; T Bartsch; A H Ahn; A MaassenVanDenBrink; U Reuter; C Tassorelli; J Schoenen; D D Mitsikostas; A M J M van den Maagdenberg; P J Goadsby
Journal:  Eur J Neurosci       Date:  2006-09       Impact factor: 3.386

4.  Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine.

Authors:  C Tassorelli; R Greco; P Morazzoni; A Riva; G Sandrini; G Nappi
Journal:  Cephalalgia       Date:  2005-08       Impact factor: 6.292

5.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

6.  K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries.

Authors:  K B Ploug; L J Boni; M Baun; A Hay-Schmidt; J Olesen; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

7.  The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid.

Authors:  E Knyihar-Csillik; A Mihaly; B Krisztin-Peva; H Robotka; I Szatmari; F Fulop; J Toldi; B Csillik; L Vecsei
Journal:  Neurosci Res       Date:  2008-05-02       Impact factor: 3.304

8.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

9.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

10.  Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally.

Authors:  V Gallai; P Sarchielli; A Floridi; M Franceschini; M Codini; G Glioti; A Trequattrini; R Palumbo
Journal:  Cephalalgia       Date:  1995-10       Impact factor: 6.292

View more
  4 in total

1.  Effects of ligustrazine on the expression of neurotransmitters in the trigeminal ganglion of a rat migraine model.

Authors:  Hui Li; Fanghui Bai; Cong Cong; Baotian Chen; Wei Xie; Shasha Li; Qiang Liu; Chaojun Chen; Yanhua Wu
Journal:  Ann Transl Med       Date:  2021-08

2.  sec-Butylpropylacetamide (SPD) has antimigraine properties.

Authors:  Dan Kaufmann; Emily A Bates; Boris Yagen; Meir Bialer; Gerald H Saunders; Karen Wilcox; H Steve White; K C Brennan
Journal:  Cephalalgia       Date:  2015-11-13       Impact factor: 6.292

3.  Expression of artemin and GFRα3 in an animal model of migraine: possible role in the pathogenesis of this disorder.

Authors:  Hai-Qiong Shang; Yan Wang; Yan-Yan Mao; Li-Gang Kong; Gao-Ying Sun; Lei Xu; Dao-Gong Zhang; Yue-Chen Han; Jian-Feng Li; Hai-Bo Wang; Zhao-Min Fan
Journal:  J Headache Pain       Date:  2016-09-06       Impact factor: 7.277

4.  Fructus Viticis methanolic extract attenuates trigeminal hyperalgesia in migraine by regulating injury signal transmission.

Authors:  Wen Wen; Huan Chen; Kun Fu; Jiangping Wei; Lixia Qin; Ting Pan; Shijun Xu
Journal:  Exp Ther Med       Date:  2019-11-15       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.